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EPISOD puts an end to sphincter of Oddi dysfunction type III
Jeff  rey D. Mosko, Ram Chuttani
Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
Summary
Th  e Rome III revision of the Milwaukee Biliary Group 
classifi   cation has long been utilized to diagnose, classify 
and drive intervention in patients with suspected sphincter 
of Oddi dysfunction (SOD). SOD Type  III is defi  ned  as 
recurrent biliary-type pain in the absence of elevated liver 
enzymes and/or imaging abnormalities (common bile duct 
<8  mm)  [1]. While patients with SOD Type  II are more 
likely to have manometric evidence of SOD (55% of the 
time), studies have shown that only 28% of patients with 
SOD Type III have manometric evidence of biliary sphincter 
dysfunction [2]. In 1989, Geenan et al showed that 17 of 
18 patients with verifi  ed SOD on manometry benefi  tted from 
endoscopic sphincterotomy [3]. Subsequent literature from 
the 1990’s revealed that patients with SOD Type  I benefi  t 
from sphincterotomy without the need for manometry. Th  ese 
studies also showed a poor correlation between the results of 
manometry and response to sphincterotomy [4-6]. Based on 
the low rate of manometric changes in SOD Type III as well as 
the aforementioned poor correlation of sphincter manometry 
with response to sphincterotomy, the optimal management for 
these patients remains a therapeutic challenge.
In the May issue of JAMA, Cotton et al [7] present a 
multi-center, prospective, sham-controlled randomized trial 
demonstrating that endoscopic sphincterotomy did not reduce 
disability due to pain in patients presenting with abdominal 
pain (suspected SOD Type III) aft  er cholecystectomy. With 
over 700,000  patients undergoing cholecystectomy every 
year [8] and greater than 10% reporting pain aft  erwards [9], 
Cotton et al set out to identify if patients with SOD Type III 
respond to endoscopic sphincterotomy (biliary and/or 
pancreatic). In addition, the ability of sphincter manometry to 
predict outcomes was evaluated. Th   e trial was conducted at 7 
tertiary centers throughout the US. Between 2008 and 2012, 
214  patients (predominantly female) post-cholecystectomy 
with suspected SOD Type  III underwent randomization. 
All patients underwent ERCP, sphincter manometry and 
were then randomized, regardless of manometry results, to 
sphincterotomy (n=141) versus sham sphincterotomy (n=73). 
Within the sphincterotomy group, patients with pancreatic 
sphincter hypertension were randomized to biliary versus dual 
(biliary and pancreatic) sphincterotomy. Both groups received 
small caliber pancreatic stents but no rectal indomethacin. Th  e 
treatment was considered successful if the patients had a low 
RAPID score (<6 days of lost productivity due to pain) at 9 
and 12 months, did not require a repeat ERCP, and/or did not 
require narcotics.
Overall, the investigators found that pain and disability 
were reduced in both groups during 12-month follow up, 
yet it was the sham sphincterotomy group (37%; 95%CI 
25.9-48.1%) that experienced successful treatment more oft  en 
than the sphincterotomy group (23%; 95%CI 15.8-29.6%). 
In patients with pancreatic sphincter hypertension, dual 
sphincterotomy (30%; 95% CI 16.7-42.9%) was equivalent to 
biliary sphincterotomy alone (20%; 95% CI 8.7-30.5%). No 
association was found between outcomes and manometry 
results. No specifi   c subgroups appeared to benefi  t  from 
sphincterotomy. Patients in an additional observational 
arm had the same success rates. Complication rates were 
reported with pancreatitis occurring in 11% and 15% of the 
sphincterotomy and sham groups respectively.
Opinion
Th  e EPISOD trial stands as the most well executed trial 
in patients with suspected sphincter of Oddi dysfunction 
to date. Among this study’s key strengths is its design. Th  e 
stringent inclusion/exclusion criteria ensured a specifi  c 
patient population. Previous studies assessed the eff  ect  of 
sphincterotomy on post-cholecystectomy pain but did not 
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specifi  cally target patients with SOD type  III. Cotton et al 
performed a thorough assessment of psychological status 
and assessed for the presence of functional gastrointestinal 
disease at enrollment [10]. While it is known that patients with 
SOD oft  en carry these comorbid conditions [11], there is no 
prior literature connecting their presence and the response to 
endoscopic therapy. Th   e authors were able to fi  rmly establish, 
as well as disprove a common misconception, that the presence 
of functional digestive disease does not predict the response 
to sphincterotomy. Finally, the authors chose objective, 
comprehensive and clinically relevant defi  nitions of success/
failure of the study intervention. Th   ey were also able to show 
that their conclusions remained in post-hoc analyses using 
less stringent defi  nitions. Th  e fact that prior sphincterotomy 
studies used re-intervention alone as an objective measure of 
treatment failure may account for previous positive results. It is 
possible that repeat endoscopic interventions were avoided 
due to their procedural risks and thus patients who were truly 
treatment failures were considered to be treatment successes.
Th   ere were very few shortcomings to this study. All patients 
underwent pancreatograms, an uncommon practice unless 
specifi   cally indicated, during ERCP to rule out pancreas 
divisum (an exclusion criterion). As well, to reduce the risk of 
post-ERCP pancreatitis, pancreatic stents were placed. Rectal 
indomethacin, which had not yet become the standard of 
care for patients at high risk for post-ERCP pancreatitis [12], 
was not used. In spite of this, the rate of pancreatitis was not 
signifi  cantly diff  erent than a recent meta-analysis reporting 
post-ERCP pancreatitis rate of 10% in patients with SOD 
versus 4% in those without [13].
So where does this leave us? Th  e EPISOD trial has 
substantiated our knowledge regarding the ineff  ectiveness of 
endoscopic sphincterotomy in patients with SOD Type  III. 
Th  e fi  ndings by Cotton et al should have major implications 
for the current paradigms of endoscopic intervention in post-
cholecystectomy patients with ongoing pain (suspected SOD 
Type III) to the point that these patients should no longer 
be off  ered ERCP and sphincterotomy. It has also led to the 
questioning of whether or not SOD Type III should remain 
a clinical entity altogether. If such patients have normal 
liver enzymes, no evidence of biliary dilation and do not 
respond to sphincterotomy, can their pain be attributed to 
true sphincter dysfunction? Should it be considered biliary at 
all? Finally, the discordance between manometry results and 
response to sphincterotomy calls sphincter manometry itself 
into question as the gold or even reference [14] standard for 
the diagnosis of SOD. It is unreliable in SOD Type I and now 
appears to be futile in SOD Type III (and potentially Type II). 
To this end, the results of prior studies that used sphincter 
manometry as the standard by which non-invasive modalities 
(e.g. HIDA scans) were measured require re-evaluation. Th  e 
Rome III consensus conference statement (2006) suggesting 
that patients with post-cholecystectomy pain should undergo 
liver and pancreatic biochemical tests followed by ultrasound, 
MRCP, and then ERCP with sphincter manometry where 
appropriate [15] remains intact but the number of patients 
where this applies has been drastically reduced. We would urge 
physicians to carefully evaluate patients with “biliary pain” 
post-cholecystectomy and use the robust conclusions from this 
study to guide their practice and avoid further harm to this 
challenging group of patients.
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